Thank you, Mr. Chair.
There was a lot of rhetoric about this bill when it was brought forth, so I think we own this collectively, or there is a responsibility to see it work. All you have to do is go back to look at the Hansards for this committee, Hansards for the House of Commons, and public statements. These are international comments that have been discussed, and at the same time, we're still not getting the result. I mean, we all understand. Nobody's naive enough to think that if we just actually produce cheap medicines it's going to solve the problems of Africa or is going to treat tuberculosis in other developing countries. For heaven's sake, the bill is even named for Africa, when it's about the entire world. That's the politics of it. But I guess the point is where do we go from this point?
I'd like to hear from each group in terms of.... I don't know if Rx and D will just stay the course. That's fine. But I'd like to know what you need to have this work. Mr. Alton has also given two suggestions that we've heard before from other groups with regard to duration of licence and the forecasting requirement, two things that I think are very important.
I'd like to hear from each organization where we go from here, in terms of solutions, to make it work for you.